As of September 19, 2023, Revance Therapeutics Inc. has projected a range of $80 million to $100 million for the non-cash impairment charges incurred due to goodwill and other assets. The company expects all associated undertakings, such as staff downsizing, to be finalized by March 31, 2024.
https://beststocks.com/revance-therapeutics-inc-projects-impairment/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.